Stay updated with breaking news from Pcr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An ideal medicine for one person may prove ineffective or harmful for someone else, and predicting who could benefit from a given drug has been difficult.
Scientists find better ways to tackle the threat of invasive fungal disease with the QIAGEN nanoplate-based dPCR system for sensitive diagnostics
Scientists find better ways to tackle the threat of invasive fungal disease with the QIAGEN nanoplate-based dPCR system for sensitive diagnostics
Two randomized trials highlighted the benefit of adding immune checkpoint inhibitors to neoadjuvant chemotherapy in patients with early high-risk estrogen receptor–positive, HER2-negative breast cancer.
The Michelangelo trial revealed that adding atezolizumab to nab-paclitaxel and carboplatin did not improve 5-year event-free survival in patients with triple-negative breast cancer.